Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
MDxHealth announced data showing that methylation of the DCR1 gene may help guide oncologists in selecting metastatic colorectal cancer patients to receive irinotecan-based therapy. The data, presented at this year’s ASCO meeting, showed that CRC patients with methylated DCR1 did not benefit from the addition of irinotecan to capecitabine therapy.
EKF Diagnostics’ Stat-Site M Hgb is a portable hemoglobin photometer. The pocket-sized device provides accurate hemoglobin analysis results within 30 seconds from 15 µL of whole blood.
Siemens Healthcare Diagnostics will collaborate with Janssen Pharmaceutica to design, develop, and commercialize a companion diagnostic test associated with an early-stage compound Janssen is developing that targets autoantibodies directed against the human β1-adrenergic receptor that may contribute to the development of heart failure.
Sysmex America was awarded a five-year Cost Per Reportable Result agreement with VA Midwest Health Care Network (VISN 23), a Veteran Integrated Service Network.
Qiagen and SIP Biotech Development have opened the Qiagen (Suzhou) Translational Medicine Center, which aims to accelerate the discovery and validation of biomarkers and to create companion diagnostics for the Chinese market. Qiagen (Suzhou) is a joint venture of Qiagen and BioBay, a life sciences cluster in Suzhou Industrial Park, near Shanghai.
Streck’s Retic-Chex Linearity, designed to establish the patient reticulocyte reportable range and linearity, is now assayed for the Sysmex XN series (XN-10 and XN-20) hematology instruments.
General Data has acquired Triangle Biomedical Sciences. TBS will become a division of General Data Healthcare, which provides specialty products and solutions to hospitals, independent labs, and other health care facilities.
Sarstedt’s S-Monovette blood collection system enables a gentle aspiration draw with no sample transfer.
Chembio Diagnostics’ Sure Check HIV 1/2 assay has received CE Mark approval. The assay is now cleared for commercialization within the EU for rapid point-of-care detection of HIV. The product is FDA approved and distributed in the United States as Clearview Complete HIV 1/2 by Alere.
Audit MicroControls has updated its logo, mission statement, and social media campaign. Audit’s mission is to supply daily QC and calibration verification/linearity materials to clinical labs worldwide while providing support, real-time data-reduction tools, same-day shipping, and quality products at a fair price.
